MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

Search

Crinetics Pharmaceuticals Inc

Closed

SectorHealthcare

29.79 0.81

Overview

Share price change

24h

Current

Min

29.16

Max

30.16

Key metrics

By Trading Economics

Income

-16M

-97M

Sales

361K

361K

EPS

-1.04

Profit margin

-26,807.202

Employees

437

EBITDA

-17M

-110M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+162.4% upside

Dividends

By Dow Jones

Next Earnings

7 Aug 2025

Market Stats

By TradingEconomics

Market Cap

-467M

2.7B

Previous open

28.98

Previous close

29.79

News Sentiment

By Acuity

50%

50%

157 / 375 Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

Crinetics Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

3 Jul 2025, 23:45 UTC

Acquisitions, Mergers, Takeovers

Orix Corp. USA to Buy Majority Stake in Hilco Global >8591.TO

3 Jul 2025, 23:42 UTC

Market Talk

Gold Edges Higher Amid U.S. Fiscal-Deficit Concerns -- Market Talk

3 Jul 2025, 23:41 UTC

Market Talk

Nikkei May Rise After Solid U.S. Jobs Data -- Market Talk

3 Jul 2025, 23:41 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3 Jul 2025, 23:15 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Beach Energy Could Smooth Path to Santos Takeover Approval -- Market Talk

3 Jul 2025, 22:59 UTC

Market Talk

Uranium Market About to Enter Lull -- Market Talk

3 Jul 2025, 22:58 UTC

Market Talk

Value Emerging in Diversified Miners Despite Headwinds -- Market Talk

3 Jul 2025, 22:47 UTC

Market Talk

Australian Household Spending Numbers Key Ahead of RBA Meeting -- Market Talk

3 Jul 2025, 22:21 UTC

Earnings

This Summer's Big TV Hit Brings Back Soap Opera Memories -- Barrons.com

3 Jul 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

3 Jul 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

3 Jul 2025, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

3 Jul 2025, 20:41 UTC

Market Talk

KKR Seen As Benefiting From Stabilizing Markets -- Market Talk

3 Jul 2025, 20:41 UTC

Market Talk

Global Equities Roundup: Market Talk

3 Jul 2025, 19:28 UTC

Market Talk

Oil Gives Back Some Gains With OPEC+ in View -- Market Talk

3 Jul 2025, 19:03 UTC

Market Talk

U.S. Natural Gas Retreats Ahead of Long Weekend -- Market Talk

3 Jul 2025, 18:34 UTC

Market Talk

Gold Has Winning Week, But Down Day -- Market Talk

3 Jul 2025, 18:18 UTC

Market Talk

Anticipation for Trump Address Gives Grain Traders Optimism -- Market Talk

3 Jul 2025, 18:06 UTC

Market Talk

Global Equities Roundup: Market Talk

3 Jul 2025, 18:06 UTC

Market Talk

Brazilian Stocks, Bonds Expected to Benefit From Benign Macro Trends -- Market Talk

3 Jul 2025, 17:27 UTC

Market Talk

U.S. Oil Rig Count Continues to Slide -- Market Talk

3 Jul 2025, 16:55 UTC

Earnings

Travel Stocks Could Offer Investors a Glorious -2-

3 Jul 2025, 16:55 UTC

Earnings

Travel Stocks Could Offer Investors a Glorious Trip, This Analyst Says -- Barrons.com

3 Jul 2025, 16:20 UTC

Market Talk

Correction to Health Care Roundup: Market Talk

3 Jul 2025, 16:15 UTC

Market Talk

Oil Futures Lose Ground in Choppy Pre-Holiday Trade -- Market Talk

3 Jul 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

3 Jul 2025, 16:05 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3 Jul 2025, 16:05 UTC

Market Talk

Gold Futures Fall Following Jobs Report -- Market Talk

3 Jul 2025, 15:47 UTC

Earnings

Honeywell Stock Is on a Roll. It Looks Ready to Break Out. -- Barrons.com

3 Jul 2025, 15:36 UTC

Earnings
Acquisitions, Mergers, Takeovers

Why It's Time to Buy This Rocks and Cement Spinoff Stock You've Probably Never Heard Of -- Barrons.com

Peer Comparison

Price change

Crinetics Pharmaceuticals Inc Forecast

Price Target

By TipRanks

162.4% upside

12 Months Forecast

Average 77.25 USD  162.4%

High 97 USD

Low 60 USD

Based on 9 Wall Street analysts offering 12 month price targets forCrinetics Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

9 ratings

9

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

30.39 / 33.46Support & Resistance

Short Term

Weak Bullish Evidence

Intermediate Term

Bearish Evidence

Long Term

Neutral Evidence

Sentiment

By Acuity

157 / 375 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.